Equity Research
Capital ideas from the industry’s brightest minds.
Our award-winning equity research analysts deliver superior investment ideas and value-added perspective for nearly 650 companies, across seven growth-oriented sectors: consumer; energy and sustainability; financial services and technology; industrials; global services; healthcare; and technology, media, and communications. William Blair’s research universe is well-diversified geographically and ranges in market capitalization with an emphasis on small- and mid-cap stocks.
-
~650
companies under
research coverage -
75%+
of coverage dedicated to small- and mid-cap growth companies
-
100+
analysts and research
professionals
As of December 31, 2024
William Blair analysts seek to cover only companies that have above-average growth prospects and above-average quality. They use multiple factors to identify high-quality companies with attractive growth prospects, including the company’s product line, level of service, and management experience.
Our clients include:
- Mutual Funds
- Investment Advisory Firms
- Banks
- Pension Funds
- Insurance Companies
- Money Managers Across North America, Europe, and Asia
Through exhaustive fundamental research and unique insight derived from independent thinking, our award-winning analysts work tirelessly to identify companies that can deliver superior investment returns for our clients.
Recent News
-
-
Karman Holdings Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Karman Holdings Inc. (KRMN $28.16), a leading merchant supplier to the U.S. missile, drone, and space industries with a key role in over 100 strategic programs. Karman made its debut on the NYSE on February 13.
-
William Blair Initiates Coverage of Seven Companies in the Obesity Treatment Space
William Blair initiated research coverage of Altimmune, Inc. (ALT $5.91), BioAge Labs, Inc. (BIOA $4.18), Corbus Pharmaceuticals Holdings, Inc. (CRBP $7.50), Skye Bioscience, Inc. (SKYE $2.89), Structure Therapeutics, Inc. (GPCR $21.09), Terns Pharmaceuticals, Inc. (TERN $3.71), and Zealand Pharma A/S (ZEAL-CSE DKK 719.00).
-
William Blair Thinking Podcast
Navigating the current market environment demands the right informational resource. That is why we launched the William Blair Thinking Podcast, which aims to provide in-depth expertise on today's financial and economic landscape.
What's different about this platform?
It's our most timely and best ideas—the ethos, if you will, of our firm's intellectual capital. All in 20 minutes. -
William Blair Shines in 2024 Coalition Greenwich Study with 12 No. 1 Rankings
William Blair, the premier global partnership with expertise in investment banking, investment management, and private wealth management, is thrilled to announce its performance in the annual Coalition Greenwich Voice of the Client – 2024 North American Equity Investors Study.
2025 Growth Stock Conference
William Blair & Company, the premier global partnership with expertise in investment banking, investment management, and private wealth management, will host its 45th Annual Growth Stock Conference June 3-5 in Chicago.
The event, to be held at Loews Chicago Hotel, has grown to become the industry’s premier generalist conference for growth investors. This must-attend forum provides an opportunity to exchange ideas with investors and top company leaders across the universe of William Blair’s research.
In 2024, more than 770 investors from around the world participated in the event, representing over 330 institutional investment firms. This year’s Growth Stock Conference features:
- Access to more than 250 participating companies
- Presenters from the highest management ranks (75% hold the chairman, CEO, president, or chief operating officer role)
- Multiple industry sectors represented across the market-cap spectrum
- One-on-one meetings between investors and company management
Featured Insights
-
Navigating the Boom: Confronting GenAI’s Most Pressing Questions
Delve into William Blair’s latest generative AI report, “Navigating the Boom: Confronting GenAI’s Most Pressing Questions.” Featuring insights from technology analysts Jason Ader, Arjun Bhatia, and Sebastien Naji, this episode explores the current state of AI, industry trends, and the future of AI development.
-
Navigating the Boom: Understanding the Economic Impact of Artificial Intelligence
From increased productivity to software development to content creation, GenAI is ushering in a new era of rapid advancement. In our first installment of confronting GenAI's most pressing questions, we explore the economic impact of AI and where the most untapped opportunities are for investors.
-
Monthly Macro with Richard de Chazal—February 2025
William Blair macro analyst Richard de Chazal reflects on February’s economic narratives, including the impact of noisy data, government spending cuts, climate change, mass deportations, recent inflation data, and the evolving nature of inflation on future monetary policy decisions.
Corporate Access
Our non-deal roadshows, conferences, and investor field trips facilitate the exchange of ideas and build relationships between senior corporate management and key decision makers with leading institutional investors.
Learn more